




NORRIS
MEDICINES LIMITED



Factory : Plot No. 901/3,4,5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

Date: 13.11.2018

To,
The Manager,
Department of Corporate Relationship,
BSE Limited
25th P. J. Towers,
Dalal Street, Fort,
Mumbai – 400 001

Scrip Code: 524414

**Subject: Submission of Standalone Unaudited Financial Results in compliance
With Regulation 33 of SEBI (LODR) Regulations, 2015**

Dear Sir,

Pursuant to Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, we submit herewith the following:

- 1) Standalone Unaudited Financial Results of the Company for the Quarter and Six months ended on 30th September, 2018.
- 2) Limited Review Report by Statutory Auditors on Standalone Unaudited Financial Results for the quarter and six months ended on 30th September, 2018.

Kindly take the aforesaid information on your record and oblige.

Thanking you,

Yours truly,
For **Norris Medicines Limited**

(Vinay Rana)
Company Secretary


Encl: As above





NORRIS

MEDICINES LIMITED



Factory : Plot No. 901/3,4,5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

STATEMENT OF UNAUDITED FINANCIAL RESULTS FOR THE QUARTER AND SIX MONTHS ENDED


Sr. No.	Particulars	(Rs. in Lakhs)					
		Quarter Ended			Six Months Ended		Year Ended
		30.09.2018 Unaudited	30.06.2018 Unaudited	30.09.2017 Unaudited	30.09.2018 Unaudited	30.09.2017 Unaudited	31.03.2018 Audited
i	Revenue from Operations	381.93	476.52	323.63	858.45	674.49	1357.12
ii	Other Income	0.27	0.04	0.82	0.31	1.39	13.91
iii	Total Revenue (i+ii)	382.20	476.56	324.45	858.76	675.88	1371.03
iv	Expenses						
	(a) Cost of Materials Consumed	173.79	394.01	183.21	567.80	306.15	678.86
	(b) Changes in Inventories of Finished Goods, work in Progress and stock in trade	89.07	-63.85	19.04	25.22	65.27	5.22
	(c) Employee Benefit Expenses	88.49	108.71	119.26	197.20	257.37	493.43
	(d) Finance Costs	18.23	17.78	19.33	36.01	36.66	69.50
	(e) Depreciation and Amortisation Expense	17.50	17.5	16.15	35.00	32.30	70.81
	(f) Other expenditure	74.32	82.39	85.01	156.71	186.42	371.56
	Total Expenses (iv)	461.40	556.54	442.00	1017.94	884.17	1689.38
v	Profit/ (Loss) before exceptional and extraordinary items and tax (iii-iv)	-79.20	-79.98	-117.55	-159.18	-208.29	-318.35
vi	Exceptional items	0	0	0	0	0	0
vii	Profit/ (Loss) before extraordinary items and tax (v-vi)	-79.20	-79.98	-117.55	-159.18	-208.29	-318.35
viii	Extraordinary items	0	0	0	0	0	0
ix	Profit/ (Loss) before Tax (vii-viii)	-79.20	-79.98	-117.55	-159.18	-208.29	-318.35
x	Tax Expense						
	(a) Current Tax	0.00	0.00	0.00	0.00	0.00	0.00
	(b) Deferred Tax	0.00	0.00	0.00	0.00	0.00	-67.12
xi	Profit / Loss after Tax	-79.20	-79.98	-117.55	-159.18	-208.29	-251.23
xii	Other Comprehensive Income	0	0	0	0	0	0
	Total Comprehensive Income for the period	-79.20	-79.98	-117.55	-159.18	-208.29	-251.23
xiii	Paid-up equity share capital (Face Value of Rs. 10/- each)	992.58	992.58	992.58	992.58	992.58	992.58
xiv	- Basic and diluted	-0.79	-0.80	-1.18	-1.59	-2.08	-2.61

Notes:

- 1) The above Unaudited Financial Results have been reviewed by the Audit Committee and approved by the Board of Directors at their respective meeting held on 13.11.2018. Limited review of the above results has been carried out by the Statutory Auditors of the company.
- 2) The Financial results of the Company have been prepared with Indian Accounting Standards (Ind AS) as prescribed under Section 133 of the Companies Act, 2013 read with relevant rules thereunder and in terms of Regulation 33 of the SEBI (Listing Obligation and Disclosure Requirements) Regulation, 2015 and SEBI circular dated 05.07.2016..
- 3) The Company is having one segment only and therefore Segmental Reporting is not applicable.
- 4) Previous year/period figures have been regrouped/rearranged wherever necessary to make them comparable with current period figures

For Norris Medicines Limited

Vimal D Shah
Managing Director




Date: 13.11.2018
Place: Ankleshwar



NORRIS


MEDICINES LIMITED



Factory : Plot No. 901/3,4,5, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Regd. Office : Plot No. 801/P, GIDC Estate,
ANKLESHWAR 393 002. (Gujarat)
Telephone : (02646) 223462, 227530
Fax : (02646) 250126
E-mail : contact@norrispharma.com
Website : www.norrispharma.com
CIN : L24230GJ1990PLC086581

STATEMENT OF ASSETS AND LIABILITIES

	As At 30.09.2018 Un audited	As At 31.03.2018 (Audited)
A . ASSETS		
1. Non Current Assets		
a) Property, Plant & Equipment	900.54	932.35
b) Capital Work in Progress		
c) Investment Property		
d) Financial Assets		
i) Investments	0.88	0.88
ii) Loans		
iii) Others	2.15	
e) Non Current Tax Assets (Net)	248.21	248.21
f) Other Non Current Assets	28.13	124.32
TOTAL NON CURRENT ASSETS	1179.91	1305.76
2. Current Assets		
a) Inventories	369.58	446.93
b) Financial Assets		
i) Trade Receivables	174.04	247.08
ii) Cash and Cash Equivalents	3.02	10.47
iii) Bank Balance other than "b" above.	0	
iv) Loans		
v) Others	61.14	58.36
TOTAL CURRENT ASSETS	607.78	762.84
TOTAL ASSETS	1787.69	2068.60
B. EQUITY & LIABILITIES		
1) Equity		
a) Equity Share Capital	992.57	992.57
b) Other Equity	-946.83	-787.65
Total Equity	45.74	204.92
2) Non Current Liabilities		
a) Financial Liabilities - Borrowings	976.14	771.42
b) Provisions		
c) Deferred Tax Laibilities (Net)		
d) Non Current Tax Liabilities (Net)		
Total Non - Current Liabilities	976.14	771.42
3) Current Liabilities		
a) Financial Liabilities		
i) Borrowings	329.44	360.06
ii) Trade payables	365.24	472.54
iii) Other financial liabilities	0	161.17
b) Other Current Liabilities	0	0.00
c) Provisions	71.13	98.49
Total Current Liabilities	765.81	1092.26
TOTAL EQUITY AND LIABILITIES	1787.69	2068.60





C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

Date : 13th November, 2018

To
The Board of Directors
Norris Medicines Limited
Ankleshwar

Limited Review Report on Standalone Quarterly Financial Results of Norris Medicines Limited to the Regulation 33 of the SEBI (Listing Obligations and Discloser Requirements) Regulations, 2015.

1. INTRODUCTION

We have reviewed the accompanying statement of Standalone unaudited financial results of **NORRIS MEDICINES LIMITED** ("the company") for the Quarter ended **30th September, 2018**, prepared and being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 as modified by SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, which has been initiated by us for the purpose of identification.

This Statement is the responsibility of the Company's Management and has been Prepared in accordance with the recognition and measurement principles laid down in Indian Accounting Standards (Ind AS) 34 "Interim Financial Reporting" prescribed under Section 133 of the Companies Act, 2013 read with the relevant rules issued thereunder and other accounting principles generally accepted in India and has been approved by the Board of directors. Our responsibility is to issue a report on the Statement based on our review.

2. SCOPE OF REVIEW

We conducted our review in accordance with the Standard on Review Engagement (**SRE**) 2410, **Review of Interim Financial Information Performed by the Independent Auditor of the Entity** issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the statement of financial results is free of material misstatement. A review is limited primarily to inquiries of company personnel and an analytical procedure applied to financial data and thus provides less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.





C-24, Ground Floor, Sardar Patel Municipal Market, Shaktinath, Bharuch - 392 001.
Tel. 02642-263302, Mobile : 98241 25540 E-mail : harishnjadav@yahoo.com

3. SCOPE OF REVIEW

Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement of unaudited financial results prepared in accordance with applicable accounting standards , i.e. Indian Accounting Standard (" Ind AS") prescribed under Section 133 of the Companies Act, 2013, read with Rule 7 of the Companies (Accounts) Rules, 2014 and other recognized accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015 read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

Place: Bharuch
Date: 13/11/2018

For, H. N. JADHAV & Co.
Chartered Accountants

C-24, Ground Floor,
Sardar Patel Municipal Market,
Shaktinath, Bharuch- 392001
Gujarat



CA HARISHCHANDRA JADAV
Proprietor
M. No. 040525
(Firm Reg. No. 103801W)